Open an account

10X Genomics

TXG · NASDAQ

$71.46+$1.57 (+2.25%)TodayMarket closed ·
Prev close $69.89

About TXG

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,178 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

Employees
1,178
Headquarters
Pleasanton, California
Listed
Sep 12, 2019
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
10xgenomics.com

TXG key statistics

Market cap
9.31B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.21M
Volume
2.86M
Open price
$69.52
High today
$73.40
Low today
$67.53
52 Week high
$102.81
52 Week low
$11.87

10X Genomics (TXG) at a glance

10X Genomics (TXG) last traded at $71.46, with a market cap of 9.31B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $67.53 and $73.40. The current price is 5.8% above the day's low and 2.6% below its high.

Volume so far is 2.86M shares, below the average of 4.21M shares a day.

Over the past year 10X Genomics has ranged from $11.87 to $102.81, and now sits 66% of the way up that range.

10X Genomics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.14 per share against an estimate of -$0.246.

The average analyst price target is $60.62, 15.2% below the current price, from 15 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

40%of 15 analyst ratings say Buy
  • Buy40.0%
  • Hold60.0%
  • Sell0.0%
Price target · 16 analystsAvg $60.62
Low
$40.40
Now
$71.46
High
$94.50

TXG earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 55.0% on average.

  1. Q3 FY24: reported -$0.30 per share against an estimate of -$0.345
  2. Q4 FY24: reported -$0.40 per share against an estimate of -$0.2976
  3. Q1 FY25: reported -$0.36 per share against an estimate of -$0.4759
  4. Q2 FY25: reported $0.28 per share against an estimate of -$0.3753
  5. Q3 FY25: reported -$0.22 per share against an estimate of -$0.291
  6. Q4 FY25: reported -$0.13 per share against an estimate of -$0.2146
  7. Q1 FY26: reported -$0.10 per share against an estimate of -$0.2945
  8. Q2 FY26: reported -$0.14 per share against an estimate of -$0.246

TXG news

  • Press releasePRNewswire

    10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026

  • Avi Kapoor

    Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday

  • Press releasePRNewswire

    10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

  • Chandrima Sanyal

    Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up

  • Press releasePRNewswire

    10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions

  • Press releasePRNewswire

    10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands

  • Chandrima Sanyal

    Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets

  • Press releasePRNewswire

    Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research

Similar companies

Companies in the same industry as 10X Genomics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.